Welcome to our dedicated page for Kardigan SEC filings (Ticker: KARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kardigan's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kardigan's regulatory disclosures and financial reporting.
Kardigan, Inc. director and 10% owner Paul L. Berns filed an initial ownership report detailing his derivative interests in the company. Most of these positions are held indirectly through ARCH Venture Fund XIII, L.P., with additional stock options held directly.
The filing lists a warrant over 876,040 shares of common stock with a $13.42 exercise price and preferred stock series (A, B and B‑1) that are convertible into common shares on a 1.5928-for-1 basis and will automatically convert upon effectiveness of Kardigan’s Form S-1 for its initial public offering. Berns also holds stock options over 33,289 and 80,224 common shares at exercise prices of $14.71 and $8.00, which vest over time and expire in 2036 and 2035, respectively.
Kardigan, Inc. reported the initial holdings of Chief Strategy Officer Andy Pasternak on Form 3. He holds stock options to acquire 358,380 shares of common stock indirectly through The Andrew J. Pasternak Spousal Lifetime Access Trust and 31,339 shares directly, all at an exercise price of $14.71 per share. The options expire on September 30, 2035 and February 9, 2036 and vest over time starting on August 1, 2025 and January 1, 2027, subject to continued service.
Kardigan, Inc.Form 3. The filing lists no transactions, no share holdings, and no derivative positions, so it serves only as a baseline disclosure of his insider status.
Kardigan, Inc. director David P. Meeker reported his existing stock option holdings on Common Stock. The filing lists three option awards: one covering 33,289 underlying shares at an exercise price of $14.7100 per share expiring on February 10, 2036, and two covering 31,856 and 80,224 underlying shares at an exercise price of $8.0000 per share expiring on April 22, 2035 and March 19, 2035, respectively.
Footnotes explain that the shares subject to certain options vest and become exercisable over time, either in three equal annual installments commencing on October 17, 2024 or on a single vesting date of February 9, 2027, in each case conditioned on Meeker’s continued service.
Kardigan, Inc. director Kimberly J. Popovits filed an initial Form 3 reporting her stock option holdings in the company. She holds three direct stock option awards over common stock, with exercise prices of $14.71 and $8.00 per share and expirations in 2035–2036. These options cover 33,289, 31,856, and 80,224 underlying shares. Footnotes state that one grant vests in three equal annual installments beginning September 23, 2024, and another vests fully on February 9, 2027, in each case subject to her continued service.
Kardigan, Inc. filed a Form 3 showing that ARCH Venture Fund XIII, L.P. and related ARCH entities hold a significant indirect stake through preferred stock and a warrant. The fund holds a warrant over 876,040 shares of common stock at an exercise price of $13.42 per share, expiring on September 4, 2035, which becomes exercisable only if certain market valuation thresholds are achieved.
The fund also holds Series A, Series B and Series B‑1 Preferred Stock, collectively convertible into common stock on a 1.5928‑for‑1 basis at any time and automatically upon effectiveness of Kardigan’s Form S‑1 for its initial public offering, without additional consideration. Various ARCH general partner entities and committee members may be deemed to share beneficial ownership of these holdings but disclaim ownership beyond their pecuniary interest.
Kardigan, Inc. Chief Medical Officer Jay Edelberg filed an initial ownership report showing both direct and indirect equity stakes. Indirectly, 4,459,840 shares of common stock are held by Edelberg Family Ventures, LLC, for which he disclaims beneficial ownership except for any pecuniary interest. He also holds 37,956 shares of common stock directly, 97,587 shares of Series B Preferred Stock that are convertible into common stock on a 1.5928-for-1 basis and will automatically convert upon effectiveness of the company’s Form S-1 for its initial public offering, and stock options over 191,136 and 95,567 shares of common stock at exercise prices of $14.71 and $8.00 per share, respectively, with vesting starting on March 13, 2026 and February 9, 2027 in monthly installments.
Kardigan, Inc. director Giordano Douglas E. reported existing stock option holdings in his initial ownership filing. He holds options over 33,289 shares of common stock at an exercise price of $14.71 per share and 80,224 shares at $8.00 per share. These options vest over time, including three equal annual installments starting on June 6, 2024, and a separate grant that vests on February 9, 2027, and expire in 2035 and 2036 if not exercised.
Kardigan, Inc. Chief Legal Officer John B. Moriarty reported his initial holdings of a stock option to buy common shares. The option covers 248,875 underlying shares at an exercise price of $23.90 per share and expires on May 11, 2036. According to the vesting terms, 25% of the shares vest on April 13, 2027, with the remainder vesting in 36 equal monthly installments, subject to his continued service. This filing does not show any buy or sell transaction, only the existing derivative position.
Kardigan, Inc. President & CEO Anastassios Gianakakos filed an initial ownership report showing a mix of direct and indirect holdings in common and preferred stock plus stock options. Direct holdings include 49,821 shares of common stock, with additional common shares held indirectly through several family trusts and by his spouse, for which he disclaims beneficial ownership except for any pecuniary interest. The filing also lists multiple stock option awards over millions of common shares with exercise prices between $8.00 and $23.90 per share, many of which vest only if Kardigan reaches specified market valuation thresholds while he remains CEO through June 6, 2027. Series A and Series B preferred stock are disclosed, each convertible into common stock on a 1.5928-for-1 basis, with automatic conversion upon effectiveness of Kardigan’s Form S-1 for its initial public offering and no stated expiration date.